Busan, South Korea

Tae-Ho Hwang

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tae-Ho Hwang

Introduction

Tae-Ho Hwang is a notable inventor based in Busan, South Korea. He has made significant contributions to the field of biotechnology, particularly in cancer research. With a focus on developing innovative methods for tumor treatment, Hwang has been awarded a total of 2 patents.

Latest Patents

Hwang's latest patents include groundbreaking work on the generation of antibodies to tumor antigens. His inventions also encompass the generation of tumor-specific complement-dependent cytotoxicity through the administration of oncolytic vaccinia virus. These patents detail methods and compositions aimed at inducing a tumor-specific antibody-mediated complement-dependent cytotoxic response in animals with tumors. The administration of a replication-competent oncolytic virus is central to his approach, as it induces the production of antibodies that specifically target the tumor.

Career Highlights

Throughout his career, Tae-Ho Hwang has worked with prominent companies in the biotechnology sector, including Sillajen, Inc. and Sillajen Biotherapeutics, Inc. His work has been instrumental in advancing therapeutic strategies for cancer treatment.

Collaborations

Hwang has collaborated with notable professionals in his field, including David H. Kirn and John Cameron Bell. These collaborations have further enriched his research and development efforts.

Conclusion

Tae-Ho Hwang's innovative work in cancer research and his patented inventions highlight his significant contributions to biotechnology. His dedication to developing effective tumor treatments continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…